Lord Abbett & CO. LLC Purchases 526,732 Shares of Danaher Corporation $DHR

Posted by Max Byerly on Jun 13th, 2026

Lord Abbett & CO. LLC grew its position in shares of Danaher Corporation (NYSE:DHR – Free Report) by 307.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 698,256 shares of the conglomerate’s stock after acquiring an additional 526,732 shares during the period. Lord Abbett & CO. LLC’s holdings in Danaher were worth $159,845,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of DHR. Norges Bank bought a new position in shares of Danaher during the 4th quarter valued at about $2,177,106,000. Viking Global Investors LP increased its position in shares of Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after purchasing an additional 2,455,994 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Danaher by 104.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock valued at $991,923,000 after purchasing an additional 2,216,789 shares during the last quarter. Generation Investment Management LLP increased its position in shares of Danaher by 34.0% during the 3rd quarter. Generation Investment Management LLP now owns 6,654,666 shares of the conglomerate’s stock valued at $1,319,354,000 after purchasing an additional 1,689,020 shares during the last quarter. Finally, Capital International Investors increased its position in shares of Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after purchasing an additional 1,487,768 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Down 0.5%

Shares of DHR stock opened at $179.95 on Friday. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52. The business has a 50-day moving average of $180.93 and a 200 day moving average of $204.78. The stock has a market capitalization of $127.37 billion, a PE ratio of 34.81, a P/E/G ratio of 2.41 and a beta of 0.81.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter last year, the business posted $1.88 EPS. The business’s revenue was up 3.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher Corporation will post 8.45 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be issued a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 annualized dividend and a yield of 0.9%. Danaher’s dividend payout ratio (DPR) is 30.95%.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Analysts Set New Price Targets

Several equities research analysts recently weighed in on DHR shares. Piper Sandler started coverage on Danaher in a report on Thursday. They set a “neutral” rating and a $200.00 target price for the company. Royal Bank Of Canada started coverage on Danaher in a report on Thursday, May 14th. They set an “outperform” rating and a $200.00 target price for the company. Wells Fargo & Company dropped their target price on Danaher from $240.00 to $212.00 and set an “equal weight” rating for the company in a report on Wednesday, April 22nd. Rothschild & Co Redburn set a $205.00 target price on Danaher in a report on Friday, April 17th. Finally, Wall Street Zen cut Danaher from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average price target of $233.61.

View Our Latest Stock Report on Danaher

Danaher Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.